A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Mantle Cell Lymphoma
B Cell Lymphoma

Interventions

DRUG: Sonrotoclax
DRUG: Zanubrutinib
DRUG: Placebo

Sponsor

BeOne Medicines